Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
---|---|---|---|---|---|
11.08. | ArriVent BioPharma GAAP EPS of -$0.90 misses by $0.20 | 1 | Seeking Alpha | ||
11.08. | ArriVent BioPharma, Inc.: ArriVent BioPharma Reports Second Quarter 2025 Financial Results | 708 | GlobeNewswire (Europe) | Positive interim Phase 1b update underscores firmonertinib's potential in EGFR PACC mutant NSCLC; global pivotal Phase 3 ALPACCA study expected to enroll first patient in 2H 2025Dosed the first patient... ► Artikel lesen | |
ARRIVENT BIOPHARMA Aktie jetzt für 0€ handeln | |||||
11.08. | ArriVent BioPharma, Inc. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
11.08. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
22.07. | ArriVent BioPharma stock maintains Buy rating at H.C. Wainwright | 1 | Investing.com | ||
21.07. | ArriVent BioPharma: Oppenheimer bestätigt Rating trotz verzögerter Studiendaten | 2 | Investing.com Deutsch | ||
21.07. | ArriVent BioPharma stock steady as Oppenheimer reiterates Outperform rating | 1 | Investing.com | ||
21.07. | ArriVent expects topline data from lung cancer drug trial in early 2026 | 3 | Investing.com | ||
21.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 1 | SEC Filings | ||
21.07. | ArriVent BioPharma, Inc.: ArriVent's Topline Pivotal Phase 3 FURVENT Data for Firmonertinib in First-Line NSCLC EGFR Exon20 Insertion Mutations is Projected to be Early 2026 | 290 | GlobeNewswire (Europe) | Enrollment in FURVENT was completed in Q1 2025 Firmonertinib received FDA Breakthrough Therapy Designation in this patient population NEWTOWN SQUARE, Pa., July 21, 2025 (GLOBE NEWSWIRE) -- ArriVent... ► Artikel lesen | |
10.07. | ArriVent BioPharma: Goldman Sachs startet Coverage mit "Buy"-Rating | 2 | Investing.com Deutsch | ||
03.07. | ArriVent BioPharma stock maintains Buy rating at Clear Street despite competitor approval | 1 | Investing.com | ||
02.07. | ArriVent BioPharma, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
02.07. | ArriVent BioPharma prices $75M equity offering | 1 | Seeking Alpha | ||
02.07. | ArriVent BioPharma, Inc.: ArriVent Announces Pricing of $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
01.07. | ArriVent BioPharma kündigt öffentliches Angebot von 75 Millionen US-Dollar an | 2 | Investing.com Deutsch | ||
01.07. | ArriVent BioPharma announces $75 million public offering | 2 | Investing.com | ||
01.07. | ArriVent announces $75M public offering | 1 | Seeking Alpha | ||
01.07. | ArriVent BioPharma, Inc.: ArriVent Announces Proposed $75 Million Public Offering of Common Stock and Pre-Funded Warrants | 1 | GlobeNewswire (USA) | ||
30.06. | ArriVent BioPharma-Aktie behält Kaufempfehlung von H.C. Wainwright nach starken NSCLC-Studiendaten | - | Investing.com Deutsch |
Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
---|---|---|---|---|---|
QIAGEN | 39,710 | +0,16 % | EQS-Adhoc: QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten Staaten an | EQS-Ad-hoc: QIAGEN N.V. / Schlagwort(e): Anleiheemission
QIAGEN N.V.: QIAGEN N.V. kündigt die Platzierung von Wandelschuldverschreibungen mit Netto-Aktienausgleich außerhalb der Vereinigten... ► Artikel lesen | |
TARSUS PHARMACEUTICALS | 58,58 | +0,72 % | Tarsus Pharmaceuticals, Inc: Tarsus Reports Second Quarter 2025 Financial Results and Recent Business Achievements | Record quarterly net product sales of $102.7 million achieved within two years of our XDEMVY® launch, an increase of 152% year over year Direct-To-Consumer campaign has activated new patients, expanded... ► Artikel lesen | |
BIONTECH | 85,65 | +0,06 % | Paukenschlag beim Übernahmekandidaten! 100 %-Aktie BioNxt Solutions lässt BioNTech und Co. hinter sich! | Die Aktie von BioNxt ist endlich angesprungen. Anfang Juli hatten wir zuletzt auf die Chancen des kanadisch-deutschen Biowissenschaftsunternehmens hingewiesen. Seitdem ist die Aktie um fast 100 % gestiegen... ► Artikel lesen | |
IMMUNOVANT | 14,690 | -0,88 % | Immunovant, Inc. - 8-K, Current Report | ||
ARS PHARMACEUTICALS | 11,610 | -9,72 % | ARS Pharma drops 9% as Lupin files application for generic neffy | ||
EVOTEC | 6,000 | +0,03 % | Die Blaupause für KI-Medikamentenentwicklung: So nutzen Evotec, NetraMark Holdings und BioNTech die neuen Möglichkeiten | Die Pharmabranche befindet sich mitten in einer Revolution. Künstliche Intelligenz verkürzt die Wirkstoffentwicklung von Jahren auf Monate und steigert die Trefferquote dramatisch. Datengetriebene Prognosen... ► Artikel lesen | |
LENZ THERAPEUTICS | 38,630 | +1,13 % | LENZ Therapeutics, Inc.: LENZ Therapeutics and Lotus Pharmaceutical Announce Exclusive License and Commercialization Agreement for LNZ100 in the Republic of Korea and Southeast Asia | SAN DIEGO and TAIPEI, Taiwan, May 09, 2025 (GLOBE NEWSWIRE) -- LENZ Therapeutics, Inc. (Nasdaq: LENZ) and Lotus Pharmaceutical Co., Ltd. ("Lotus", TWSW Stock Code: 1795) today announced an exclusive... ► Artikel lesen | |
SUMMIT THERAPEUTICS | 23,710 | -2,91 % | H.C. Wainwright hebt Kursziel für Summit Therapeutics auf 50 US-Dollar an | ||
AVIDITY BIOSCIENCES | 46,540 | -4,20 % | Avidity Biosciences, Inc.: Avidity Biosciences Reports Second Quarter 2025 Financial Results and Recent Highlights | Aligned with FDA on del-brax accelerated and full approval pathways for FSHD, reported positive topline data from Phase 1/2 FORTITUDE trial, and initiated global... ► Artikel lesen | |
RAPPORT THERAPEUTICS | 17,630 | +4,94 % | Rapport Therapeutics, Inc.: Rapport Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update | Results of positron emission tomography (PET) trial and second multiple ascending dose (MAD-2) trial support RAP-219's transformative potential for epilepsy and other central nervous system (CNS)... ► Artikel lesen | |
CRISPR THERAPEUTICS | 44,200 | -0,45 % | 1 Reason Every Investor Should Know About CRISPR Therapeutics (CRSP) | ||
RECURSION PHARMACEUTICALS | 4,690 | -3,60 % | If You'd Invested $1,000 in Recursion Pharmaceuticals 4 Years Ago, Here's How Much You'd Have Today | ||
ADMA BIOLOGICS | 17,255 | -0,72 % | ADMA Biologics, Inc.: ADMA Biologics Announces Second Quarter 2025 Financial Results and Provides Business Update | 2Q 2025 Total Revenue of $122.0 Million, a 14% YoY Increase, and a 29% YoY Increase Excluding a Prior Year Non-Recurring Item 2Q 2025 GAAP Net Income of $34.2 Million, a 7% YoY Increase 2Q 2025 Adjusted... ► Artikel lesen | |
DYNE THERAPEUTICS | 13,480 | -1,96 % | Dyne Therapeutics stock rises after Raymond James upgrade to Strong Buy | ||
ARCELLX | 69,43 | -1,17 % | Arcellx, Inc. (ACLX) Reports 97% Response Rate in CAR-T Trial |